Last reviewed · How we verify
NCT07405645: MRg-FUS
Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy
NA trial testing ExAblate Neuro in Head Neck Cancer in 20 participants. Currently enrolling.
31 December 2028
Quick facts
| Lead sponsor | University of Virginia |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 20 |
| Start date | 15 February 2026 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 December 2029 |
| Sites | 6 locations across United States |
Drugs / interventions tested
- ExAblate Neuro
Conditions studied
- Head Neck Cancer — all drugs for Head Neck Cancer →
- Squamous Cell Cancer of Head and Neck (SCCHN) — all drugs for Squamous Cell Cancer of Head and Neck (SCCHN) →
- Cancer Pain — all drugs for Cancer Pain →
Sponsor
University of Virginia
Who can join
Adults 18 to 85, any sex, with Head Neck Cancer or Squamous Cell Cancer of Head and Neck (SCCHN). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase 1 multi-site study investigates the safety and initial effectiveness of focused ultrasound lesioning of the contralateral mesencephalon for severe, opioid-resistant pain associated with head and neck cancer and brachial cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07405645
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ExAblate Neuro
Trials testing the same drug.
- NCT03894553 — Focused Ultrasound (FUS) Mesencephalotomy for Head & Neck Cancer Pain · NA · completed
Other recruiting trials for Head Neck Cancer
Currently open trials in the same condition.
- NCT06736379 — Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer · Phase 1 · recruiting
- NCT06642324 — Human Papillomavirus Association and Genomic Exploration in Head-Neck Squamous Cell Carcinomas · recruiting
- NCT05878964 — Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors. · recruiting
- NCT05382585 — Newer Therapeutic Targets in Head and Neck Cancers · recruiting
Other University of Virginia trials
Trials by the same sponsor.
- NCT05880355 — Multimodality Cardiovascular Imaging for the Translation of Therapies for Vascular Activation After MI · EARLY_PHASE1 · not yet recruiting
- NCT07146685 — Effect of Local Anesthetic Concentration on Rebound Pain: A Randomized Control Study · Phase 4 · not yet recruiting
- NCT07298941 — Resilience Enhancement Following Sleep Treatment · Phase 2 · recruiting
- NCT07036315 — Meaning in Music-Based Pain Modulation · NA · recruiting
- NCT07010146 — Role of Estrogen on Skeletal Outcomes in FHA · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07405645 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Virginia
- Last refreshed: 12 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07405645.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing